Parameswaran Hari

Company: Obsidian Therapeutics

Job title: Chief Development Officer

Seminars:

Armoring Tumor-Infiltrating Lymphocytes (TIL) with Membrane-Bound IL-15 Improves T-Cell Phenotype & Enhances Persistence in Melanoma 9:30 am

OBX-115 engineered TIL therapy utilizes the cytoDRiVE® platform to enable regulation of membrane-bound IL15 (mbIL15) using a drug-responsive domain (DRD), obviating the need for IL2 administration mbIL15 selectively expands CD8+ T-cells with no IL2-like toxicity and reduced exhaustion, while supporting antitumor activity and persistence, and can re-activate expansion of persistent antigen-experienced OBX-115 TIL OBX-115 TIL…Read more

day: Post-Conference Day - Tackling Solid Tumors